For biotech and pharma teams serving smaller patient populations, such as those with rare diseases and sub-indications, there are a number of unique hurdles to getting the intelligence needed to deliver new treatments and improve patient outcomes.
However, some brands are getting creative with real-world data and analytics strategies in order to better understand true market need, friction points in the patient experience and factors driving outcomes.
In this Conversations in Healthcare panel, Clarivate’s Mike Ward joined industry experts to discuss: